 |
Journal articles
What do we learn from HER2-positive breast cancer genomic profiles?
Abstract : ABSTRACT: Patients with a tumor presenting amplification of the HER2 gene are currently proposed trastuzumab (herceptin) and this has greatly changed their outcome. However, a number of HER2-positive cancers show intrinsic or acquired resistance to trastuzumab and there are clear indications that they form a heterogeneous group of tumors. A paper in this issue of Breast Cancer Research addresses this heterogeneity at the genomic level.
https://www.hal.inserm.fr/inserm-00491423
Contributor : Yves Le Ster Connect in order to contact the contributor
Submitted on : Friday, June 11, 2010 - 3:47:52 PM
Last modification on : Tuesday, July 5, 2022 - 9:16:01 AM
Long-term archiving on: : Friday, September 17, 2010 - 1:26:40 PM
Contributor : Yves Le Ster Connect in order to contact the contributor
Submitted on : Friday, June 11, 2010 - 3:47:52 PM
Last modification on : Tuesday, July 5, 2022 - 9:16:01 AM
Long-term archiving on: : Friday, September 17, 2010 - 1:26:40 PM
Files
bcr2571_Theillet_edited.pdf
Files produced by the author(s)